A signature characteristic of a biased GPCR ligand is the capability to activate either of the G-protein subtypes (Gαs, Gαq/11, Gαi/o, or Gα12/13) for selectively mobilizing and exploiting specifically selected GPCR-mediated downstream signaling pathway in various metabolic disease systems, including cancer [176]. This evidence concerns the gene LPAR3 and metabolic disease.